Takeda Pharmaceutical Co. Ltd. has begun dosing in an international Phase III clinical program with its candidate prophylactic vaccine for dengue, TAK-003, closing the gap on the only commercialized product for the viral infection, Sanofi Pasteur's Dengvaxia.
The Japanese company's placebo-controlled TIDES study will investigate the activity of the live-attenuated tetravalent vaccine against all four virus serotypes,...







